News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
405,688 Results
Type
Article (22533)
Company Profile (71)
Press Release (383405)
Multimedia
Podcasts (91)
Webinars (15)
Section
Business (137869)
Career Advice (1071)
Deals (22626)
Drug Delivery (104)
Drug Development (50956)
Employer Resources (84)
FDA (9060)
Job Trends (8884)
News (205490)
Policy (19080)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (1353)
Academic (1)
Accelerated approval (35)
ADA (17)
Adcomms (9)
Allergies (133)
Alliances (33134)
ALS (137)
Alzheimer's disease (1034)
Antibody-drug conjugate (ADC) (382)
Approvals (9604)
Artificial intelligence (505)
ASCO (185)
Autoimmune disease (216)
Automation (37)
Bankruptcy (179)
Best Places to Work (6669)
BIO (38)
Biologics (1)
BIOSECURE Act (9)
Biosimilars (205)
BioSpace Insights (101)
Biotechnology (39)
Bladder cancer (103)
Brain cancer (62)
Breast cancer (424)
Cancer (3634)
Cardiovascular disease (330)
Career advice (943)
Career pathing (33)
CAR-T (183)
CDC (17)
Cell therapy (509)
Cervical cancer (36)
Clinical research (44744)
Collaboration (1693)
Commercialization (6)
Company closure (4)
Compensation (483)
Complete response letters (60)
COVID-19 (2252)
CRISPR (85)
C-suite (967)
Cystic fibrosis (111)
Data (4944)
Decentralized trials (1)
Denatured (36)
Depression (108)
Dermatology (68)
Diabetes (286)
Diagnostics (3561)
Digital health (31)
Diversity (8)
Diversity, equity & inclusion (23)
Drug discovery (299)
Drug pricing (139)
Drug shortages (16)
Duchenne muscular dystrophy (158)
Earnings (44170)
Editorial (32)
Employer branding (8)
Employer resources (83)
Events (58191)
Executive appointments (865)
FDA (11525)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (6)
Frontotemporal dementia (19)
Funding (1274)
Gene editing (163)
Generative AI (48)
Gene therapy (365)
GLP-1 (673)
Government (2371)
Grass and pollen (7)
Guidances (240)
Healthcare (8031)
Hematology (113)
HIV (52)
Huntington's disease (27)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (86)
Immunology and inflammation (148)
Immuno-oncology (68)
Indications (161)
Infectious disease (2434)
Inflammatory bowel disease (134)
Inflation Reduction Act (10)
Influenza (78)
Intellectual property (206)
Interviews (174)
IPO (9944)
IRA (38)
Job creations (2452)
Job search strategy (776)
JPM (35)
Kidney cancer (17)
Labor market (58)
Layoffs (276)
Leadership (31)
Legal (4522)
Licensing (11)
Liver cancer (57)
Longevity (24)
Lung cancer (512)
Lymphoma (307)
Machine learning (31)
Management (33)
Manufacturing (840)
Marketing (8)
MASH (132)
Medical affairs (1)
Medical device (4866)
Medtech (4947)
Mergers & acquisitions (13633)
Metabolic disorders (879)
mRNA (152)
Multiple sclerosis (104)
NASH (15)
Neurodegenerative disease (251)
Neuropsychiatric disorders (73)
Neuroscience (2017)
Neurotech (1)
NextGen: Class of 2026 (2922)
Non-profit (1699)
Now hiring (27)
Obesity (437)
Opinion (201)
Ovarian cancer (106)
Pain (192)
Pancreatic cancer (179)
Parkinson's disease (243)
Partnered (19)
Patents (406)
Patient recruitment (441)
Peanut (27)
People (40501)
Pharmaceutical (36)
Pharmacy benefit managers (22)
Phase 1 (12602)
Phase 2 (19211)
Phase 3 (16231)
Pipeline (6490)
Policy (185)
Postmarket research (1715)
Preclinical (5315)
Press Release (38)
Prostate cancer (200)
Psychedelics (40)
Radiopharmaceuticals (224)
Rare diseases (734)
Real estate (3605)
Recruiting (34)
Regulatory (15698)
Reports (23)
Research institute (1345)
Resumes & cover letters (129)
Rett syndrome (18)
RNA editing (17)
RSV (39)
Schizophrenia (118)
Series A (255)
Series B (199)
Service/supplier (2)
Sickle cell disease (78)
Special edition (14)
Spinal muscular atrophy (97)
Sponsored (21)
Startups (2629)
State (2)
Stomach cancer (10)
Supply chain (84)
Tariffs (74)
The Weekly (53)
Vaccines (669)
Venture capital (79)
Weight loss (236)
Women's health (97)
Worklife (16)
Date
Today (43)
Last 7 days (224)
Last 30 days (1304)
Last 365 days (16583)
2026 (10863)
2025 (16570)
2024 (19207)
2023 (22341)
2022 (30648)
2021 (32951)
2020 (31522)
2019 (23898)
2018 (18428)
2017 (19419)
2016 (18365)
2015 (21641)
2014 (17069)
2013 (14200)
2012 (15079)
2011 (15628)
2010 (13976)
Location
Africa (465)
Alabama (53)
Alaska (4)
Arizona (134)
Arkansas (9)
Asia (38204)
Australia (4916)
California (7174)
Canada (2552)
China (1535)
Colorado (356)
Connecticut (297)
Delaware (266)
Europe (60402)
Florida (1160)
Georgia (133)
Hawaii (3)
Idaho (30)
Illinois (661)
India (112)
Indiana (386)
Iowa (10)
Japan (575)
Kansas (97)
Kentucky (26)
Louisiana (17)
Maine (14)
Maryland (880)
Massachusetts (5604)
Michigan (87)
Minnesota (373)
Mississippi (5)
Missouri (62)
Montana (14)
Nebraska (11)
Nevada (49)
New Hampshire (30)
New Jersey (2490)
New Mexico (14)
New York (2109)
North Carolina (1044)
North Dakota (6)
Northern California (3635)
Ohio (184)
Oklahoma (12)
Oregon (28)
Pennsylvania (1456)
Puerto Rico (21)
Rhode Island (29)
South America (684)
South Carolina (17)
South Dakota (1)
Southern California (2924)
Tennessee (109)
Texas (929)
United States (26485)
Utah (184)
Vermont (2)
Virginia (267)
Washington D.C. (53)
Washington State (612)
West Virginia (2)
Wisconsin (91)
Wyoming (3)
405,688 Results for "shanghai hengrui pharmaceuticals co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Visionary Holdings’ Subsidiary Nanjing Tuoyuanjian Health Technology Co., Ltd. Enters into Distribution Agreement with Suncare (Shanghai) Health Technology Co., Ltd.
Collaboration Expected to Expand the Commercialization of Stem Cell Aesthetic and Anti-Aging Products Through an AI-Enabled Community Healthcare and Senior Care Network in China
July 29, 2026
·
4 min read
Press Releases
Shanghai Kinbio Tech Co., Ltd. Announces Strategic Expansion with New Kinbionova Showroom in San Diego
July 8, 2026
·
1 min read
Business
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.
May 12, 2026
·
2 min read
·
Tristan Manalac
Obesity
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending
New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.
July 7, 2026
·
4 min read
·
Gabrielle Masson
Press Releases
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
June 30, 2026
·
8 min read
Press Releases
Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
August 19, 2026
·
3 min read
Press Releases
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
June 7, 2026
·
13 min read
Manufacturing
Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time
An inspection of a facility making Elevar’s rivoceranib uncovered deficiencies, leading the FDA to reject a combination therapy that includes the drug. The rebuff is the third strike for the partners after the agency issued manufacturing-related denials for the other drug in the combo.
July 15, 2026
·
1 min read
·
Nick Paul Taylor
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
February 10, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
June 1, 2026
·
5 min read
1 of 40,569
Next
